Treatment with PIO improved IR and PH and reversed the lower expression of adiponectin in perivascular and PPAR-γ in the pulmonary artery, highlighting this drug as potential benefit for this poorly recognized complication of obesity. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.